Equities

Seres Therapeutics Inc

Seres Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.7686
  • Today's Change0.037 / 5.03%
  • Shares traded1.58m
  • 1 Year change-31.38%
  • Beta2.0015
Data delayed at least 15 minutes, as of Nov 22 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments128181291
Total Receivables, Net8.67--0
Total Inventory30----
Prepaid expenses9.121313
Other current assets, total------
Total current assets175195304
Property, plant & equipment, net13213436
Goodwill, net------
Intangibles, net------
Long term investments--00.50
Note receivable - long term------
Other long term assets41105.19
Total assets359349355
LIABILITIES
Accounts payable3.641714
Accrued expenses231816
Notes payable/short-term debt000
Current portion long-term debt/capital leases00.460
Other current liabilities, total724953
Total current liabilities998682
Total long term debt1025125
Total debt1025125
Deferred income tax------
Minority interest------
Other liabilities, total203202116
Total liabilities403338223
SHAREHOLDERS EQUITY
Common stock0.140.130.09
Additional paid-in capital933875746
Retained earnings (accumulated deficit)(978)(865)(614)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total0(0.01)(0.06)
Total equity(45)11132
Total liabilities & shareholders' equity359349355
Total common shares outstanding13512592
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.